BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
OPDIVO (nivolumab) by Bristol Myers Squibb is programmed death receptor-1-directed antibody interactions [moa]. Approved for programmed death receptor-1 blocking antibody [epc]. First approved in 2014.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPDIVO (nivolumab) is a monoclonal antibody that blocks programmed death receptor-1 (PD-1), a key immune checkpoint, to reinvigorate anti-tumor immunity. It is approved for multiple cancer indications including melanoma, non-small cell lung cancer, renal cell carcinoma, and others. The drug works by unleashing T-cell mediated tumor destruction through checkpoint inhibition.
$0.051BPart D
PeakStable
Peak-stage franchise with established market presence supporting mature brand and commercial excellence teams at Bristol Myers Squibb.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Started Nov 2026
30 enrolled
Untreated MelanomaUnresectable MelanomaMetastatic Melanoma
Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Started Oct 2026
28 enrolled
Unresectable Cutaneous Melanoma
PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Started Aug 2026
68 enrolled
Diffuse Midline GliomaDiffuse Midline High-grade GliomaMedulloblastoma+1 more
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Started Jul 2026
26 enrolled
Non-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Recurrent
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Started Jul 2026
120 enrolled
HER2-negativeGastroesophageal JunctionEsophageal Adenocarcinoma+1 more
Worked on OPDIVO at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.